A decade's overview of 2-aminothiophenes and their fused analogs as promising anticancer agents

Donia G Darwish; Hany A M El-Sherief; Salah A Abdel-Aziz; Gamal El-Din A Abuo-Rahma

doi:10.1002/ardp.202300758

A decade's overview of 2-aminothiophenes and their fused analogs as promising anticancer agents

Arch Pharm (Weinheim). 2024 Mar 5:e2300758. doi: 10.1002/ardp.202300758. Online ahead of print.

Authors

Donia G Darwish¹, Hany A M El-Sherief¹, Salah A Abdel-Aziz^{1

2}, Gamal El-Din A Abuo-Rahma^{1

3}

Affiliations

¹ Department of Pharmaceutical Chemistry, Faculty of Pharmacy, Deraya University, New Minia, Minia, Egypt.
² Department of Pharmaceutical Chemistry, Faculty of Pharmacy, Al-Azhar University, Assiut Branch, Assiut, Egypt.
³ Department of Medicinal Chemistry, Faculty of Pharmacy, Minia University, Minia, Egypt.

PMID: 38442316
DOI: 10.1002/ardp.202300758

Abstract

Over the past decades, cancer has been a challenging domain for medicinal chemists as it is an international health concern. In association, small molecules such as 2-aminothiophenes and their derivatives showed significant antitumor activity through variable modes of action. Therefore, this article aims to review the advances regarding these core scaffolds over the past 10 years, where 2-aminothiophenes and their fused analogs are classified and discussed according to their biological activity and mode of action, in the interest of boosting new design pathways for medicinal chemists to develop targeted antitumor candidates.

Keywords: 2-aminothiophene; HDAC inhibitors; antitumor; kinase inhibitors; thieno[2,3-d]pyrimidine.

Publication types

Review

Grants and funding

None